<! DOCTYPE = html>
<html>
<title>CS657 - Prescription</title>
<style>
div.container {
		width: 100%;
		border: 1px solid gray;
}

header{
		padding: 0.5em;
		#color: black;
		background-color: orange;
		clear: left;
		text-align: center;
}
.footer{
		padding : 1em;
		background-color: orange;
		text-align: center;
		<!--- position: fixed;>
		bottom : 0;
		width : 100%;
}

nav {
		float: left;
		max-width: 160px;
		margin: 0;
		padding: 1em;
}

nav ul {
		list-style-type: none;
		padding: 0;
}
	 
nav ul a {
		text-decoration: none;
}

article {
		margin-left: 170px;
		border-left: 1px solid gray;
		padding: 1em;
		overflow: hidden;
}
table {
		font-family: arial, sans-serif;
		border-collapse: collapse;
		width: 80%;
}

td, th {
		border: 4px solid #000000;
		text-align: middle;
		padding: 8px;
}

tr:nth-child(even) {
		background-color: #eeeeee;
}	

div.box {
		background-color: white;
		width: 300px;
		border: 2px solid green;
		padding: 10px;
		margin: 25px;
}
</style>
<body>
<div class="container">
	<header><h1>
		IIT Kanpur Medical Labs</h1>
	</header>
	<hr>	<h2> Precription for the query: </h2>
	<div class="box">
	anorexia
	</div>
	<hr>	<h2>
		Identified Disease: </h2>
	<div class="box">
	Nutrition Disorders
	</div>
	<hr>	<h2>More Symptoms: </h2>
	<div class="box">
	Emaciation, Cyanosis, Ataxia, Learning Disorders, Quadriplegia
	</div>
		<hr><h2>
Medication:</h2>
<table>
	<tr>
		<th>Serial No</th>
		<th>Drug Name</th>
		<th>Group</th>
		<th>Indication</th>
	</tr>	<tr>
		<td>1.</td>
		<td>Casein</td>
		<td>Approved</td>
		<td>Not Available</td>
	</tr>	<tr>
		<td>2.</td>
		<td>Omega-3 fatty acids</td>
		<td>Approved, Nutraceutical</td>
		<td>Provided as daily supplements. Aa preparation of omega-3-acid ethyl esters is licensed in UK for prevention of recurrent events after myocardial infarction in addition to treatment of hypertriglyceridaemia. </td>
	</tr>	<tr>
		<td>3.</td>
		<td>Icosapent</td>
		<td>Approved, Nutraceutical</td>
		<td>EPA can be used for lowering elevated triglycerides in those who are hyperglyceridemic. In addition, EPA may play a therapeutic role in patients with cystic fibrosis by reducing disease severity and may play a similar role in type 2 diabetics in slowing the progression of diabetic nephropathy.</td>
	</tr>	<tr>
		<td>4.</td>
		<td>Xanthan gum</td>
		<td>Approved</td>
		<td>Not Available</td>
	</tr>	<tr>
		<td>5.</td>
		<td>Ammonium molybdate</td>
		<td>Approved</td>
		<td>Not Available</td>
	</tr>	<tr>
		<td>6.</td>
		<td>Invert sugar</td>
		<td>Approved</td>
		<td>Invert sugar presents a large variety of uses. It can be used therapeutically for parenteral hyperalimentation[6] or to be used as an excipient with a known effect.[10] Invert sugar is also approved for its use in food products as a humectant, crystallization modifier, and liquid and nutritive sweetener.[7]</td>
	</tr>	<tr>
		<td>7.</td>
		<td>Fish oil</td>
		<td>Approved, Nutraceutical</td>
		<td>Not Available</td>
	</tr>	<tr>
		<td>8.</td>
		<td>Fursultiamine</td>
		<td>Approved</td>
		<td>Not Available</td>
	</tr>	<tr>
		<td>9.</td>
		<td>Olive oil</td>
		<td>Approved</td>
		<td>For use in adults as a source of calories and fatty acids in total parenteral nutrition [FDA Label]. Sometimes used as an additive in cosmetic products.</td>
	</tr>	<tr>
		<td>10.</td>
		<td>Cupric Chloride</td>
		<td>Approved, Investigational</td>
		<td>For use as a supplement to intravenous solutions given for total parenteral nutrition (TPN).</td>
	</tr>	<tr>
		<td>11.</td>
		<td>Docosahexaenoate</td>
		<td>Approved, Investigational</td>
		<td>Not Available</td>
	</tr>	<tr>
		<td>12.</td>
		<td>Safflower oil</td>
		<td>Approved, Investigational</td>
		<td>Not Available</td>
	</tr>	<tr>
		<td>13.</td>
		<td>Iodine</td>
		<td>Approved, Investigational</td>
		<td>Investigated for use/treatment in breast disorders (unspecified) and pain (acute or chronic).</td>
	</tr>	<tr>
		<td>14.</td>
		<td>Phylloquinone</td>
		<td>Approved, Investigational</td>
		<td>For the treatment of haemorrhagic conditions in infants, antidote for coumarin anticoagulants in hypoprothrombinaemia.</td>
	</tr>	<tr>
		<td>15.</td>
		<td>Iron protein succinylate</td>
		<td>Approved, Investigational</td>
		<td>Not Available</td>
	</tr>	<tr>
		<td>16.</td>
		<td>Acetylcarnitine</td>
		<td>Approved, Investigational</td>
		<td>Acetylcarnitine is not approved for any indication in the United states and Canada, but it is approved and indicated in Italy for cerebrovascular disorders, mental function disorders, peripheral nerve disorders, diabetic neuropathy, and nutritional supplementation; Portugal for mental function disorders; Argentina for cerebral vasculopathy, nutritional supplementation, and peripheral neuropathy; Chile for dementia; Philippines for cerebrovascular disorders and mental function disorders; Australia for nutritional supplementation; and India for nutritional supplementation to increase sperm count. Acetylcarnitine also has several potential therapeutic indications for which it is still being investigated: in Norway, acetylcarnitine is in a phase IV trial for prophylactic treatment of migraines; in Italy acetylcarnitine is in a phase II trial for use in patients with type 2 Diabetes Mellitus, a phase III trial for alleviating fatigue in patients with chronic hepatitis C, and for use in patients with Minimal Hepatic Encephalopathy; in the United States acetylcarnitine is in a phase II trial for the neurodegenerative disorder Progressive Supranuclear Palsy, a phase II and III trial for reducing peripheral neuropathy in cancer patients as an adjunct to chemotherapy, a phase I and II trial for treating patients in septic shock, a phase II trial for bipolar depression, a phase II trial to reduce oxidative stress in patients with Sickle Cell disease, a phase I and II trial for chronic fatigue syndrome, and a study for preventing nerve damage in HIV patients; in China acetylcarnitine is in a phase III trial for reducing peripheral neuropathy in cancer patients as an adjunct to chemotherapy; in the United Kingdom acetylcarnitine is being investigated for preventing nerve damage in HIV patients; and in Israel acetylcarnitine is being studied for the treatment of male infertility.</td>
	</tr>	<tr>
		<td>17.</td>
		<td>Benzoic Acid</td>
		<td>Approved, Investigational</td>
		<td>Not Available</td>
	</tr>	<tr>
		<td>18.</td>
		<td>Amino acids</td>
		<td>Approved, Investigational</td>
		<td>Not Available</td>
	</tr>	<tr>
		<td>19.</td>
		<td>Ferumoxytol</td>
		<td>Approved, Investigational</td>
		<td>Investigated for use/treatment in anemia, kidney disease, and cardiovascular disorders.</td>
	</tr>	<tr>
		<td>20.</td>
		<td>Sotirimod</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in actinic keratosis and skin infections/disorders.</td>
	</tr>	<tr>
		<td>21.</td>
		<td>LX6171</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in alzheimer's disease, attention deficit/hyperactivity disorder (ADHD), dementia, neurologic disorders, and schizophrenia and schizoaffective disorders.</td>
	</tr>	<tr>
		<td>22.</td>
		<td>Opebacan</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in crohn's disease, congenital anomaly (unspecified), cardiovascular disorders, pediatric indications, and burns and burn infections.</td>
	</tr>	<tr>
		<td>23.</td>
		<td>GW 597599</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in adverse effects (chemotherapy), anxiety disorders, depression, and gastrointestinal diseases and disorders (miscellaneous).</td>
	</tr>	<tr>
		<td>24.</td>
		<td>Ilodecakin</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in inflammatory disorders (unspecified), crohn's disease, and rheumatoid arthritis.</td>
	</tr>	<tr>
		<td>25.</td>
		<td>Usistapide</td>
		<td>Investigational</td>
		<td>Not Available</td>
	</tr></table>
<div class="footer"> Copyright &copy : IIT Kanpur
</div>	
</div>
</body>
</html>